Older Adults
Psychedelic research involving older adults is gaining traction, highlighting the potential therapeutic benefits of compounds such as psilocybin and MDMA. Recent studies suggest promising safety profiles and efficacy, paving the way for future clinical applications in this demographic.
Key Insights
- 1
Recent systematic reviews indicate that older adults participate less frequently in psychedelic clinical trials, yet when they do, they often show high tolerance and positive responses to treatment.
- 2
Studies suggest psilocybin-assisted therapy can significantly improve mood and cognitive flexibility in older adults suffering from depression.
- 3
Safety data from recent trials indicate a favourable risk-benefit profile for psychedelics in the older population, with few adverse effects reported.
- 4
Psychedelic experiences can enhance emotional resilience, which is particularly beneficial for older adults grappling with loss and existential anxiety.
What is Older Adults?
Older adults often experience various mental health disorders, such as major depressive disorder and anxiety, which can severely impact their quality of life.
The pathophysiology of these conditions can be complex, involving neurobiological and psychosocial factors, making treatment challenging.
Symptoms of these disorders in older adults may include persistent sadness, loss of interest in social activities, and cognitive decline, which are often exacerbated by isolation and physical health issues.
Current Treatments
Standard-of-care treatments for mental health disorders in older adults include pharmacotherapy (e.g., SSRIs, SNRIs) and psychotherapy, although these may have limited efficacy and significant side effects in this population.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Older Adults.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Numerous studies demonstrate significant mental health improvements in elderly patients treated with psilocybin. | Large | High | Consistent |
| MDMA Promising results in reducing anxiety and enhancing therapeutic rapport in older adults with PTSD. | Medium | Moderate | Consistent |
| Ketamine Some evidence supports its efficacy in treatment-resistant depression, but research in older adults is still emerging. | Medium | Moderate | Inconsistent |
Psilocybin and Older Adults
Psilocybin, a naturally occurring psychedelic compound, has shown remarkable efficacy in alleviating symptoms of depression and anxiety among older adults. Clinical trials have demonstrated that a single administration can lead to sustained improvements in emotional well-being and cognitive flexibility, potentially transforming how mental health disorders are treated in the elderly.
MDMA and Older Adults
MDMA, known for its empathogenic effects, may enhance the therapeutic alliance between patients and therapists in a clinical setting. For older adults dealing with trauma-related conditions, MDMA-assisted therapy can facilitate emotional processing, resulting in significant reductions in anxiety and improvement in quality of life.
Clinical Outlook
The future of psychedelic treatment for older adults looks promising, with ongoing research likely to expand the understanding of safe and effective use. As attitudes towards psychedelics continue to evolve, it is expected that these treatments may become integral components of mental health care for the elderly, particularly in managing treatment-resistant conditions.
Industrial Landscape
Key players in the psychedelic research field involve non-profits such as the Multidisciplinary Association for Psychedelic Studies (MAPS) and the Beckley Foundation, alongside pharmaceutical companies exploring psychedelics for therapeutic use.
Quick Indicators
Organisations
Search →Janssen Research & Development
Janssen Research & Development is the pharmaceutical research and development arm of Johnson & Johnson (J&J). Operating under J&J's Innovative Medicine division, Janssen has sponsored clinical trials into ketamine-derived compounds, including esketamine (Spravato), the first FDA-approved psychedelic-adjacent treatment for treatment-resistant depression.
Dana-Farber Cancer Institute
Ketamine Research Institute
The Ketamine Research Institute is a US-based clinical research organization developing precision medicine approaches to ketamine infusion therapy, studying optimized dosing protocols to treat depression and offering clinician training in evidence-based ketamine practice.
University of California, San Francisco
University of California, San Francisco (UCSF) hosts major psychedelic research activity through the Translational Psychedelic Research Program (TrPR), Neuroscape Psychedelics Division, and psychiatry-led clinical research on psychedelic-assisted therapies.
Usona Institute
Usona Institute is a US-based 501(c)(3) non-profit medical research organisation (MRO) headquartered in Madison, Wisconsin. Co-founded in 2014 by Bill Linton (CEO of Promega Corporation) and Malynn Utzinger, M.D., Usona was established after Linton witnessed the profound impact of a Johns Hopkins psilocybin study on a terminally ill friend. Unlike commercial drug developers, Usona operates as a mission-driven MRO — conducting and supporting pre-clinical and clinical research on psilocybin and other consciousness-expanding medicines, with the goal of developing accessible, affordable treatments. Its research leadership includes Dr. Charles Raison (Director of Clinical and Translational Research, UW-Madison psychiatrist) and Dr. Alexander Sherwood (medicinal chemist). Usona's psilocybin programme received FDA Breakthrough Therapy Designation for major depressive disorder in 2019. After completing the Phase 2 PSIL201 study (the largest Phase 2 randomised controlled trial of psilocybin for MDD at the time), the Institute launched the Phase 3 uAspire trial in 2024 — a 240-participant, randomised, double-blind, multicentre study comparing 25 mg psilocybin vs placebo in adults with MDD. Usona is also exploring 5-MeO-DMT in early-stage research.
Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai is a leading US academic medical institution home to the Parsons Research Center for Psychedelic Healing, which runs rigorous clinical trials of MDMA- and psilocybin-assisted therapies for PTSD and trauma in veteran and civilian populations.
Massachusetts General Hospital
The Center for the Neuroscience of Psychedelics aims to better understand how psychedelics can be used to improve the treatment of mental illnesses. The core mission of the center is to understand exactly how psychedelics enhance the brain's capacity for change—or neuroplasticity—to optimize current treatments and render the term treatment resistant obsolete.
Emory University
The Center for Psychedelics and Spirituality at Emory University combines expertise in psychiatry with spiritual health to better understand the therapeutic promise of psychedelics as medicine. Launched at the end of 2022, the group works towards making psychedelic-assisted therapies more effective within a wide cultural and spiritual context.
Johns Hopkins University
The Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
University of Nebraska
At the University of Nebraska Medical Centre research with psychedelics is underway. At the UN Medical Centre, Associate Professor of Palliative Medicine, Lou Lukas is using psychedelics to improve the quality of life of people in palliative care. Dr Lukas is part of a wider research team consisting of various medical professionals affiliated with the University of Nebraska that explores the use of psychedelics in palliative care. The Heartland Palliadelic Research Centre was created to complement existing disease-based research by exploring the potential of psychedelics to help people with serious illness increase resilience and reduce suffering for themselves and their families.
Washington University School of Medicine in St. Louis
The Program in Psychedelic Research (PiPer) is a partnership between The Healthy Mind Lab, the Washington University Neuroimaging Lab, and Usona Institute. PiPer leverages 30 years of neuroimaging research and four decades of psychiatry research. The group has started with four research projects around neuroimaging data in humans and animals. The university also serves as a site for Usona's Phase II/III trial with 25mg of psilocybin.
Council On Spiritual Practices
The Council on Spiritual Practices (CSP) is a US non-profit organisation founded in 1993 by Robert Jesse to support research and education on the safe and effective use of entheogens and primary religious experience. CSP was instrumental in initiating the landmark Johns Hopkins psilocybin research programme with Roland Griffiths, co-funding pivotal early studies on psilocybin's mystical-experience effects that re-established psychedelic science and shaped clinical frameworks globally.
People
Search →Robin Murphy
Researcher at the University of Auckland School of Pharmacy
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Aaron Klaiber
Doctoral researcher at the University of Basel
He appears as an author on multiple controlled human psychedelic studies spanning DMT, mescaline, MDMA, LSD, and psilocybin, suggesting a substantial role in contemporary psychopharmacology research.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Kate Godfrey
Research Associate at Imperial College London’s Centre for Psychedelic Research
Kate Godfrey is notable for contributing to leading human psychedelic research on microdosing, neuroimaging, and neuroplasticity at Imperial College London.
Joshua Di Vincenzo
MSc researcher / clinical research staff member at the University Health Network and University of Toronto
He coauthors multiple systematic reviews and real-world studies on ketamine for treatment-resistant depression, making him a visible contributor to the evidence base on psychedelic-adjacent psychiatric therapeutics.
Yvan Beaussant
Instructor in Medicine at Harvard Medical School and palliative care physician at Dana-Farber Cancer Institute
He is a leading clinical researcher in psychedelic-assisted therapy for serious illness, especially cancer-related depression, demoralization, and existential distress.
Neşe Devenot
Senior Lecturer in the University Writing Program at Johns Hopkins University
Neşe Devenot is a notable critic and scholar of psychedelic medicine whose work examines ethics, public discourse, and the social meanings of psychedelic-assisted therapy.
Bing Cao
PhD researcher at the Key Laboratory of Cognition and Personality, Faculty of Psychology, Southwest University
He is a recurring coauthor on multiple ketamine and psychedelic-adjacent systematic reviews and mechanistic studies, making him a visible contributor to contemporary rapid-acting antidepressant research.
Michael Mueller
Researcher in Psychedelic Research & Therapy Development at the Psychiatric University Clinic Zurich and University of Zurich
He is a leading clinical researcher on ayahuasca-inspired DMT/harmine formulations, contributing to randomized trials and mechanistic studies on their pharmacology, cognition, and psychiatric potential.
Thomas Swift
Assistant Professor in Chemistry at the University of Bradford
He is a coauthor on several qualitative psychedelic-therapy papers that help characterize patient experience, insight, and therapeutic mechanisms in psilocybin and MDMA-assisted treatment.
Elena Argento
Researcher and postdoctoral scholar at the University of British Columbia / BC Centre on Substance Use
Elena Argento is notable for community-based research on psychedelics, sexual health, and substance use, including studies on marginalized women, ayahuasca-assisted therapy, and potential psychedelic-related reductions in suicidality and opioid use.
Connected Evidence
The latest clinical data and verified academic findings associated with Older Adults.